-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 3, GlaxoSmithKline (GSK) issued a press release stating that the new indications of Rapidone (generic name: Lamotrigine Dispersible Tablets) have been approved by the National Medical Products Administration (NMPA).
Bipolar disorder is a disease that can cause severe fluctuations in mood, vitality, and ability to perform daily tasks.
Lamotrigine is a voltage-based sodium channel blocker.
The results of two international phase 3 clinical trials for bipolar disorder showed that compared with placebo, lamotrigine significantly delayed the intervention of any affective episode for up to 197 days, and the effect was similar to that of lithium salt; it was different from lithium salt Compared with placebo, lamotrigine significantly delayed the intervention time to depressive episode.
According to the press release, GSK lamotrigine dispersible tablets have been approved for new indications for bipolar disorder, which will bring more treatment options for such patients, thereby helping to improve the quality of life and prognosis of patients.
